| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | D W Miles | |
| J Burchell | |||
| J Taylor-Papadimitriou | |||
| M Dalziel | |||
| P2860 | cites work | Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3 | Q24311744 |
| Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine | Q71659957 | ||
| Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide | Q71699068 | ||
| Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: Antibody binding to synthetic peptide epitopes | Q72067897 | ||
| Alterations of O-glycan biosynthesis in human colon cancer tissues | Q72203074 | ||
| Processing O-glycan core 1, Gal beta 1-3GalNAc alpha-R. Specificities of core 2, UDP-GlcNAc: Gal beta 1-3 GalNAc-R(GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase and CMP-sialic acid: Gal beta 1-3GalNAc-R alpha 3-sialyltransferase | Q72750319 | ||
| Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer | Q72768948 | ||
| Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin | Q73300727 | ||
| Low O-acetylation of sialyl-Le(x) contributes to its overexpression in colon carcinoma metastases | Q73503250 | ||
| Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation | Q73562880 | ||
| Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines | Q73717919 | ||
| Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumor-associated aberrations in glycosylation | Q73850281 | ||
| Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 | Q74033284 | ||
| An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1) | Q74559831 | ||
| Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components | Q24312497 | ||
| Cloning and expression of cDNA for a human Gal(beta1-3)GalNAc alpha2,3-sialyltransferase from the CEM T-cell line | Q24324122 | ||
| Human mucin gene MUC4: organization of its 5'-region and polymorphism of its central tandem repeat array | Q24530913 | ||
| Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen | Q24563666 | ||
| Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion | Q28237260 | ||
| Innate immunity: the virtues of a nonclonal system of recognition | Q29614428 | ||
| Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. | Q33820583 | ||
| Three genes that encode human β-galactoside α2,3-sialyltransferases. Structural analysis and chromosomal mapping studies | Q34303681 | ||
| Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells | Q34304405 | ||
| Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group | Q34322325 | ||
| Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. | Q34411297 | ||
| Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. All putative sites within the tandem repeat are glycosylation targets in vivo | Q34440632 | ||
| Mucin genes and the proteins they encode: structure, diversity, and regulation | Q35537772 | ||
| Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients | Q36081647 | ||
| A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans | Q36254705 | ||
| 99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection | Q36294993 | ||
| CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity | Q36380885 | ||
| Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein | Q37375709 | ||
| Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells | Q37396123 | ||
| Determination of the site-specific O-glycosylation pattern of the porcine submaxillary mucin tandem repeat glycopeptide. Model proposed for the polypeptide:galnac transferase peptide binding site | Q38346855 | ||
| A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. | Q40242537 | ||
| MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines | Q40433320 | ||
| Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice | Q40934020 | ||
| Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine | Q41065506 | ||
| Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. | Q41444956 | ||
| Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene | Q41581624 | ||
| Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy | Q41594089 | ||
| Antibodies to the cytoplasmic domain of the MUC1 mucin show conservation throughout mammals | Q41623438 | ||
| Structures of acidic O-linked polylactosaminoglycans on human skim milk mucins | Q44888350 | ||
| Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. | Q47705298 | ||
| Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide | Q47975807 | ||
| Tissue-specific regulation of mouse core 2 beta-1,6-N-acetylglucosaminyltransferase | Q48043975 | ||
| Report on the first international workshop on carcinoma-associated mucins | Q53398836 | ||
| Delayed mammary tumor progression in Muc-1 null mice. | Q53459080 | ||
| Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies | Q53818020 | ||
| MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral | Q57594342 | ||
| The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM | Q58975867 | ||
| A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas | Q69075433 | ||
| A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes | Q69103942 | ||
| Isolation and characterization of mucin-like glycoprotein in human milk fat globule membrane | Q70311926 | ||
| Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells | Q70993699 | ||
| A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma | Q71153705 | ||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 301-313 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | MUC1 and cancer | |
| P478 | volume | 1455 |
| Q48336166 | A Boronic Acid Assay for the Detection of Mucin-1 Glycoprotein from Cancer Cells. |
| Q37076880 | A Contra Capture Protein Array Platform for Studying Post-translationally Modified (PTM) Auto-antigenomes |
| Q59113329 | A Novel Approach of Targeted Immunotherapy against Adenocarcinoma Cells with Nanoparticles Modified by CD16 and MUC1 Aptamers |
| Q36958112 | A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. |
| Q30907994 | A family of secreted mucins from the parasitic nematode Toxocara canis bears diverse mucin domains but shares similar flanking six-cysteine repeat motifs. |
| Q39228070 | A histochemical approach to glycan diversity in the urothelium of pig urinary bladder. |
| Q31051574 | A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized |
| Q39837844 | A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells |
| Q33250468 | A serum glycomics approach to breast cancer biomarkers |
| Q33849708 | A tumor specific antibody to aid breast cancer screening in women with dense breast tissue |
| Q90479566 | Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research |
| Q37581540 | Altered tumor-cell glycosylation promotes metastasis |
| Q34391018 | An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells |
| Q37538136 | Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations |
| Q38901814 | Antibody induction directed against the tumor-associated MUC4 glycoprotein |
| Q36746758 | Apical MUC1 expression revealed on the foveolar epithelium in H. pylori gastritis |
| Q38240594 | Aptamers as drug delivery vehicles. |
| Q73589027 | CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases |
| Q98386021 | CD146, from a melanoma cell adhesion molecule to a signaling receptor |
| Q34494018 | Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response |
| Q34522222 | Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening |
| Q51121599 | Chemoenzymatic synthesis of a MUC1 glycopeptide carrying non-natural sialyl TF-beta O-glycan. |
| Q39805251 | Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis |
| Q27931058 | Coding repeat instability in the FLO11 gene of Saccharomyces yeasts |
| Q36752265 | Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways |
| Q33293976 | DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours |
| Q40789473 | Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody |
| Q38293250 | Determination of the site-specific oligosaccharide distribution of the O-glycans attached to the porcine submaxillary mucin tandem repeat. Further evidence for the modulation of O-glycans side chain structures by peptide sequence |
| Q80778789 | Differential expression of MUC1 and carbohydrate antigens in primary and secondary head and neck squamous cell carcinoma |
| Q44503051 | Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. |
| Q33520919 | Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation |
| Q47126640 | Electrochemical and optical biosensors for early-stage cancer diagnosis by using graphene and graphene oxide. |
| Q34503522 | Elevated Golgi pH in breast and colorectal cancer cells correlates with the expression of oncofetal carbohydrate T-antigen |
| Q55447627 | Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis? |
| Q37711887 | Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma |
| Q57515385 | Engineering O-Glycosylation Points in Non-extended Peptides: Implications for the Molecular Recognition of Short Tumor-Associated Glycopeptides |
| Q33671557 | Engineering of N. benthamiana L. plants for production of N-acetylgalactosamine-glycosylated proteins - towards development of a plant-based platform for production of protein therapeutics with mucin type O-glycosylation |
| Q90532496 | Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer |
| Q51874223 | Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. |
| Q38560347 | Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases |
| Q58039395 | Expression and glycosylation of MUC1 in epidermolysis bullosa-associated and sporadic cutaneous squamous cell carcinomas |
| Q54987325 | Expression of Ly-6D on the surface of normal and neoplastic mammary epithelial cells of the mouse. |
| Q36209663 | Expression of MUC1 in esophageal squamous-cell carcinoma and its relationship with prognosis of patients from Linzhou city, a high incidence area of northern China |
| Q79972618 | Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance |
| Q85212499 | Expression of aberrantly glycosylated Mucin‐1 in ovarian cancer |
| Q38897800 | Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer |
| Q34207920 | Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. |
| Q31032067 | Formation of lactones from sialylated MUC1 glycopeptides. |
| Q38307814 | Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. |
| Q51079321 | Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells. |
| Q24792808 | Gene Therapy Applications to Cancer Treatment |
| Q90332533 | Generation of Novel Anti-MUC1 Monoclonal Antibodies with Designed Carbohydrate Specificities Using MUC1 Glycopeptide Library |
| Q34988382 | Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing |
| Q53458801 | Glycodelin reduces breast cancer xenograft growth in vivo. |
| Q47691736 | Glycosylation Changes in Brain Cancer |
| Q38366332 | Glycosylation alterations in lung and brain cancer |
| Q30658777 | Glycosylations versus conformational preferences of cancer associated mucin core |
| Q37876406 | Golgi pH, its regulation and roles in human disease |
| Q34528973 | Heterogeneity of high-molecular-weight human salivary mucins. |
| Q38950523 | Highly specific electrochemical analysis of cancer cells using multi-nanoparticle labeling |
| Q40794467 | Human MUC1 mucin: a potent glandular morphogen |
| Q54758220 | Hypervariability of the membrane-associated mucin and cancer marker MUC1. |
| Q50908486 | Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice. |
| Q40620016 | Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors |
| Q51036586 | Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant. |
| Q35759802 | Immunohistochemical and biochemical characterization of mucin in pseudomyxoma peritonei: a case study |
| Q29346979 | Immunohistochemical evidence of Muc1 expression during rat embryonic development |
| Q36239661 | Immunotherapy for gynaecological malignancies. |
| Q34071695 | Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line |
| Q36695056 | Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme. |
| Q39516745 | Improved method for immunostaining of mucin separated by supported molecular matrix electrophoresis by optimizing the matrix composition and fixation procedure. |
| Q28288802 | Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer |
| Q46585315 | Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma |
| Q39690197 | Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. |
| Q42706133 | Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. |
| Q30582061 | Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis |
| Q39696121 | Interactions of mucins with the Tn or Sialyl Tn cancer antigens including MUC1 are due to GalNAc-GalNAc interactions. |
| Q38894517 | Label-free in vivo molecular imaging of underglycosylated mucin-1 expression in tumour cells |
| Q92172790 | Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma |
| Q36868517 | Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision |
| Q40644424 | Liquid chromatography mass spectrometry-based O-glycomics to evaluate glycosylation alterations in gastric cancer |
| Q34427407 | Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo. |
| Q56864756 | MUC1 (EMA) : une molécule clé de la carcinogenèse ? |
| Q41024242 | MUC1 O-glycosylation contributes to anoikis resistance in epithelial cancer cells |
| Q24599141 | MUC1 and MUC4: switching the emphasis from large to small |
| Q84963446 | MUC1 and the simple mucin-type antigens: Tn and Sialyl-Tn are differently expressed in salivary gland acini and ducts from the submandibular gland, the vestibular folds, and the soft palate |
| Q40505299 | MUC1 expression in human prostate cancer cell lines and primary tumors |
| Q40671358 | MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue |
| Q38951257 | MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis |
| Q35635449 | MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling |
| Q40339235 | MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas |
| Q60300117 | MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer |
| Q37737313 | MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy |
| Q24601584 | Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells |
| Q36221411 | Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures. |
| Q30782803 | Molecular characteristics of non-small cell lung cancer |
| Q37916658 | Molecular imaging with nucleic acid aptamers |
| Q38946727 | Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo |
| Q44595746 | Mucin Core Peptide Expression Can Help Differentiate Barrett's Esophagus From Intestinal Metaplasia of the Stomach |
| Q44192048 | Mucin core O-glycosylation is modulated by neighboring residue glycosylation status. Kinetic modeling of the site-specific glycosylation of the apo-porcine submaxillary mucin tandem repeat by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases |
| Q55438762 | Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells. |
| Q26740541 | Mucin-Type O-Glycosylation in Gastric Carcinogenesis |
| Q90080269 | Mucins as a New Frontier in Pulmonary Fibrosis |
| Q39476569 | Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by φC31 integrase |
| Q38355328 | Newcastle Disease Virus Hemagglutinin Neuraminidase as a Potential Cancer Targeting Agent. |
| Q28481099 | Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro |
| Q28476756 | Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro |
| Q37586838 | Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. |
| Q39651366 | O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model |
| Q37380703 | One Step Assembly of Thin Films of Carbon Nanotubes on Screen Printed Interface for Electrochemical Aptasensing of Breast Cancer Biomarker |
| Q40314964 | PankoMab: a potent new generation anti-tumour MUC1 antibody |
| Q36328299 | Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets |
| Q53229242 | Peanut agglutinin appearance in the blood circulation after peanut ingestion mimics the action of endogenous galectin-3 to promote metastasis by interaction with cancer-associated MUC1. |
| Q44558660 | Pleural fluid viscosity may help identifying malignant pleural effusions |
| Q34198013 | Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines. |
| Q80305801 | Potential tumor markers for human gastric cancer: an elevation of glycan:sulfotransferases and a concomitant loss of alpha1,2-fucosyltransferase activities |
| Q33521473 | Preparation of biomolecule microstructures and microarrays by thiol-ene photoimmobilization |
| Q44297118 | Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen |
| Q61851735 | Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game |
| Q33649651 | Recent advances in cellular glycomic analyses. |
| Q40675473 | Regulated expression of MUC1 epithelial antigen in erythropoiesis |
| Q47118046 | Ripening-induced chemical modifications of papaya pectin inhibit cancer cell proliferation |
| Q46117515 | SCWISh network is essential for survival under mechanical pressure. |
| Q39594793 | Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. |
| Q43856190 | Serine versus threonine glycosylation with α-O-GalNAc: unexpected selectivity in their molecular recognition with lectins. |
| Q44527454 | Site-specific characterisation of densely O-glycosylated mucin-type peptides using electron transfer dissociation ESI-MS/MS. |
| Q35608604 | Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images |
| Q31056671 | Small molecule inhibitors of mucin-type O-linked glycosylation from a uridine-based library |
| Q27675884 | Solution structure of a truncated anti-MUC1 DNA aptamer determined by mesoscale modeling and NMR |
| Q59103157 | Specific MUC1 Splice Variants Are Correlated With Tumor Progression in Esophageal Cancer |
| Q57594296 | Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen |
| Q24630985 | Structure, evolution, and biology of the MUC4 mucin |
| Q46113336 | Synthesis and application of N-[1-(4-(4-fluorophenyl)-2,6-dioxocyclohexylidene)ethyl] (Fde)-protected amino acids for optimization of solid-phase peptide synthesis using gel-phase (19)F NMR spectroscopy |
| Q35030845 | Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope |
| Q39254744 | Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates |
| Q39650206 | Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen–Friedenreich Antigen and a Fluorine‐Substituted Analogue |
| Q41983543 | Synthetic glycopeptides and glycoproteins with applications in biological research |
| Q44613798 | Synthetic glycopeptides for the development of tumour-selective vaccines |
| Q45194251 | Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response |
| Q42487727 | Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. |
| Q38197051 | The Cosmc connection to the Tn antigen in cancer |
| Q57567888 | The Production and Characterization of Novel Heavy-Chain Antibodies Against the Tandem Repeat Region of MUC1 Mucin |
| Q64092764 | The Role of the Cell Surface Mucin MUC1 as a Barrier to Infection and Regulator of Inflammation |
| Q37831859 | The Tn antigen-structural simplicity and biological complexity |
| Q35751618 | The characterisation of mucin in a mature ovarian teratoma occurring in an eight year old patient |
| Q36187831 | The chemistry and biology of mucin-type O-linked glycosylation |
| Q34290892 | The chemistry and immunochemistry of blood group A, B, H, and Lewis antigens: past, present and future |
| Q34365135 | The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma |
| Q40855480 | The lectin domain of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities |
| Q34622638 | The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression |
| Q31705505 | The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. |
| Q38100999 | The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. |
| Q79298695 | Tissue and Serum MUC1 Mucin Detection in Breast Cancer Patients |
| Q42138158 | Total chemical synthesis of proteins without HPLC purification |
| Q37962848 | Toward automated oligosaccharide synthesis |
| Q40109569 | Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes |
| Q45871048 | Transfected human dendritic cells to induce antitumor immunity |
| Q51836026 | Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions. |
| Q57006955 | Tumor-Associated MUC1 Tandem-Repeat Glycopeptide Microarrays to Evaluate Serum- and Monoclonal-Antibody Specificity |
| Q40656064 | Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas |
| Q49590854 | Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma |
| Q30660122 | Using in silico transcriptomics to search for tumor-associated antigens for immunotherapy |
| Q85818776 | Value of metastin receptor immunohistochemistry in predicting metastasis after radical nephrectomy for pT1 clear cell renal cell carcinoma |
| Q73943713 | [Clinical utility of serous tumoural markers] |
Search more.